Skip to main content
. 2017 Jul 26;18:39. doi: 10.1186/s12865-017-0222-z

Fig. 5.

Fig. 5

VEGF/VEGFR2 and VEGF/VEGFR1 blocking activities in patients that completed the trial vaccination scheme. a VEGF/VEGFR2 blocking activity according to the different vaccination cohorts. b VEGF/VEGFR1 blocking activity according to the different vaccination cohorts. Patients that has shown at least one serum sample with neutralizing anti-VEGF antibodies were considered with a positive blocking activity on the VEGF/VEGFR1 or VEGF/VEGFR2 bindings